Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $46.00 price target on the biotechnology company’s stock. D. Boral Capital’s target price indicates a potential upside of 443.09% from the company’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $8.47 on Wednesday. The business has a 50-day moving average of $9.94 and a 200 day moving average of $7.70. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The firm has a market cap of $718.43 million, a P/E ratio of -16.29 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. As a group, research analysts predict that Anavex Life Sciences will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AVXL. Orion Capital Management LLC grew its holdings in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new position in Anavex Life Sciences during the 3rd quarter valued at about $74,000. Atria Investments Inc purchased a new position in Anavex Life Sciences during the 3rd quarter valued at about $76,000. BNP Paribas Financial Markets grew its holdings in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 7,421 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Anavex Life Sciences by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 6,366 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.